Skip to content
synovial sarcoma foundation
  • About
    • Mission
    • Initiatives
    • Affiliations
    • Leadership
    • Board of Directors
    • Medical Advisory Board
    • Careers
  • Resources
    • Synovial Sarcoma FAQ
    • Treatments
    • Clinical Trials & Therapies
    • Synovial Sarcoma Patient Survey
    • Synovial Sarcoma Tumor Board
    • Patient Stories
    • Patient Resources
    • Eddie’s Story
    • Video Resources
    • SSF Ambassador Program
  • Research Programs
    • Clinical Research
    • Tumor Glow
    • Synovial Sarcoma Registry
  • Latest News
Donate

Send us a note

Please fill out the form below and we will gladly respond as soon as possible.



    Clinical Trial, Latest News

    Two New TCR-NK Cell Therapy Trials Now Recruiting for Synovial Sarcoma

    October 2, 2026 ayushis Comments Off on Two New TCR-NK Cell Therapy Trials Now Recruiting for Synovial Sarcoma
    A gloved hand uses a dropper to add blue liquid into a row of clear glass test tubes in a laboratory setting.

    Two clinical trials testing TCR-NK cell therapy for advanced synovial sarcoma are now recruiting patients, one in the United States and one in the United Kingdom. Both use donor-derived natural killer cells engineered to target proteins commonly found on synovial sarcoma tumors.

    What Is TCR-NK Cell Therapy?

    TCR-NK therapy works differently from the TCR-T cell therapies patients may already be familiar with. Natural killer (NK) cells from healthy donors are engineered to carry a T-cell receptor (TCR), which helps the NK cells find a protein that many synovial sarcoma tumors carry. The US trial targets NY-ESO-1, and the UK trial targets MAGE-A4.

    Because the cells come from donors rather than being manufactured from each patient’s own cells, they are prepared in advance instead of requiring individual cell collection and processing. In both trials, patients receive a short course of chemotherapy before the cell infusion to help the new cells take hold.

    Eligibility Depends on Two Tests

    Each trial accepts patients whose tumor carries the trial’s target protein and whose immune type matches. Two tests determine eligibility:

    Test 1: HLA Type, a blood test that identifies your immune type. The US trial accepts HLA-A02:01, A02:05, or A02:06. The UK trial requires HLA-A02:01.

    Test 2: Tumor Antigen, a test on tumor tissue showing which target protein it carries. The US trial requires NY-ESO-1. The UK trial requires MAGE-A4 positivity.

    The United States Trial

    Run at MD Anderson Cancer Center in Houston (NY-ESO-1 TCR/IL-15 NK, NCT06083883), this Phase I/Ib trial is recruiting patients ages 16 to 80.

    Key eligibility includes:

    • HLA-A02:01, A02:05, or A*02:06 positive
    • NY-ESO-1 expressed in at least 50% of tumor cells, confirmed at MD Anderson
    • Prior systemic therapy including doxorubicin and/or ifosfamide
    • Measurable disease
    • Prior cell therapy allowed after three months, but no prior NY-ESO-1 therapy

    The United Kingdom Trial

    Sponsored by Zelluna (ZI-MA4-1, NCT07613723), this Phase 1 trial is recruiting at The Royal Marsden in London and The Christie in Manchester, for patients ages 18 to 75.

    Key eligibility includes:

    • HLA-A*02:01 positive
    • Tumor tests positive for MAGE-A4
    • Inoperable, locally advanced or metastatic synovial sarcoma
    • At least one prior line of cancer therapy
    • Measurable disease
    • No prior cell or gene therapy

    Next Steps: Ask Your Oncologist About Testing

    Talk with your oncologist about HLA and tumor antigen testing to find out whether either trial is an option for you. Full eligibility details and other synovial sarcoma trials are available at synovialsarcoma.org/clinical-trials-and-therapies.

    Trial details from ClinicalTrials.gov, September 2026.

    • #AllogeneicCellTherapy
    • #AskYourOncologist
    • #AYACancer
    • #CancerImmunotherapy
    • #CancerResearch
    • #CancerSurvivor
    • #CellTherapy
    • #ClinicalResearch
    • #ClinicalTrials
    • #Houston
    • #Immunotherapy
    • #KnowYourOptions
    • #London
    • #MAGEA4
    • #Manchester
    • #MDAnderson
    • #NKCells
    • #NowRecruiting
    • #NYESO1
    • #OffTheShelf
    • #PatientAdvocacy
    • #PatientRecruitment
    • #RareCancer
    • #RoyalMarsden
    • #Sarcoma
    • #SarcomaAwareness
    • #SarcomaCommunity
    • #SarcomaWarrior
    • #SynovialSarcoma
    • #TCRNK
    • #TheChristie
    • #UKCancer
    • #Zelluna
    ayushis

    Post navigation

    Previous
    Next

    Search

    Categories

    • Black Flag Racing (2)
    • Case Study (5)
    • Children (1)
    • CHOP (3)
    • Clinical Trial (4)
    • Development (12)
    • Dr. Theodore Laetsch (3)
    • Education (27)
    • Europe Expansion (1)
    • Healthcare (13)
    • Latest News (22)
    • Patient Story (1)
    • Programs (1)
    • Rare Cancer (7)
    • Rare Cancer Funding (2)
    • Research (21)
    • SSF Ambassador Program (1)
    • Synovial Sarcoma Conference (2)
    • Synovial Sarcoma Registry (7)
    • Teresa Belluco (1)
    • Tumor Board (2)

    Recent posts

    • A doctor in a white coat with a stethoscope around their neck holds a tablet device, standing in a medical setting with a patient lying on a bed in the background.
      Synovial Sarcoma of the Tibial Nerve: A Case of Diagnostic Ambiguity and Limb Salvage
    • A scientist wearing blue gloves adjusts a microscope slide.
      Can We Reactivate T Cells After TCR-T Therapy Stops Working?
    • Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
      Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    Tags

    #AYACancer #CancerResearch #CaseReport #CellTherapy #ClinicalTrials #Immunotherapy #KnowYourOptions #MAGEA4 #MolecularDiagnostics #NYESO1 #PatientAdvocacy #RareCancer #RareDisease #Sarcoma #SarcomaAwareness #SoftTissueSarcoma #SS18SSX #SynovialSarcoma #SynovialSarcomaFoundation #TumorBoard Afami-cel Afamitresgene autoleucel Cancer Research CHOP immunotherapy MAGE-A4 synovial sarcoma NY-ESO-1 synovial sarcoma precision medicine Rare Cancer rare cancer research rare soft tissue sarcoma research sarcoma research sarcoma treatment soft tissue sarcoma Synovial Sarcoma synovial sarcoma biomarker testing synovial sarcoma diagnosis Synovial Sarcoma Foundation synovial sarcoma immunotherapy synovial sarcoma treatment T-Cell Therapy targeted therapy TCR Therapy TECELRA

    Related posts

    A doctor in a white coat with a stethoscope around their neck holds a tablet device, standing in a medical setting with a patient lying on a bed in the background.
    Case Study, Education

    Synovial Sarcoma of the Tibial Nerve: A Case of Diagnostic Ambiguity and Limb Salvage

    November 11, 2026 ayushis Comments Off on Synovial Sarcoma of the Tibial Nerve: A Case of Diagnostic Ambiguity and Limb Salvage

    A case report published in the Journal of Orthopaedic Case Reports by Varun R Mehta, Rajkumar Mehta, Rahul Parmar, and Sonal R Mehta from Mehta Hospital and V Care Hospital in Gujarat, India, documents a rare synovial sarcoma (SS) arising from the tibial nerve. Only five such cases have ever been reported in medical literature. […]

    Webinar recording poster titled “Inside the Synovial Sarcoma Foundation” featuring speakers Nathan Imperiale and Philip Leider, recorded October 9, 2026, and sponsored by US WorldMeds.
    Education, Latest News

    Two Leaders, One Mission: Nathan Imperiale and Philip Leider on Synovial Sarcoma

    October 20, 2026 ayushis Comments Off on Two Leaders, One Mission: Nathan Imperiale and Philip Leider on Synovial Sarcoma

    Our Chairman of the Board of Directors, Nathan Imperiale, was recently invited by Philip Leider, President of the Board of the Sarcoma Alliance, to present about the Synovial Sarcoma Foundation in a live webinar hosted by the Sarcoma Alliance. The conversation covered the Foundation’s origin story, our active research programs, and the resources available to […]

    Transparent blue spheres with molecular structures inside float near visible DNA double helix strands, creating a scientific and futuristic background focused on genetics and biotechnology.
    Education, Research

    Synovial Sarcoma of the Hyoid Bone: A Rare Case

    October 12, 2026 ayushis Comments Off on Synovial Sarcoma of the Hyoid Bone: A Rare Case

    A case report by Ryan Toledo, Jennifer Khong, and colleagues (published August 31, 2026; DOI: 10.7812/TPP/26.039) describes only the third known synovial sarcoma arising from the hyoid bone, a small U-shaped bone in the neck. The patient, a 62-year-old man, remains disease-free years after treatment. The Case The patient had a slowly growing left-sided neck […]

    The Synovial Sarcoma Foundation is a registered 501(c)(3) nonprofit organization. Tax ID number is 33-4027591. Contributions to the Synovial Sarcoma Foundation are tax-deductible to the extent permitted by law.

    • Terms & conditions
    • Privacy policy
    synovial sarcoma foundation
    • community@synovialsarcoma.org
    1025 Thomas Jefferson St. NW, Suite W-3200, Washington DC 20007
    Facebook-f X-twitter Linkedin

    Navigation

    • About
    • Research Programs
    • Patient Stories
    • Resources

    Stay in touch